

Gouji Toyokawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5417039/publications.pdf>

Version: 2024-02-01

107
papers

2,702
citations

172443

29
h-index

223791

46
g-index

107
all docs

107
docs citations

107
times ranked

4295
citing authors

#	ARTICLE	IF	CITATIONS
1	IgG4-Related Lung Disease Exhibiting the Invasion into the Diaphragm: A Case Report. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2022, 28, 223-226.	0.8	2
2	Histological background of dedifferentiated solitary fibrous tumour. <i>Journal of Clinical Pathology</i> , 2022, 75, 397-403.	2.0	4
3	Clinical significance of part-solid lung cancer in the eighth edition TNM staging system. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 34, 219-226.	1.1	5
4	ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK inhibitors: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1761-1764.	1.9	4
5	The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 975-988.	2.4	10
6	Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2198-2204.	1.9	19
7	Prognostic value of postoperative decrease in serum albumin on surgically resected early-stage non-small cell lung carcinoma: A multicenter retrospective study. <i>PLoS ONE</i> , 2021, 16, e0256894.	2.5	7
8	Radiologic Features of Resected Lung Adenocarcinoma With Epithelial-Mesenchymal Transition. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1647-1655.	1.3	0
9	Significance of the Red Blood Cell Distribution Width in Resected Pathologic Stage I Nonsmall Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 32, 1036-1045.	0.6	10
10	Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 914-920.	1.3	19
11	Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2830-2839.	1.9	4
12	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1217-1225.	2.5	42
13	Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 467-477.	2.8	40
14	Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. <i>Thoracic Cancer</i> , 2019, 10, 1779-1787.	1.9	7
15	Spread through air spaces in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, S1881-S1884.	1.4	1
16	18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 13362.	3.3	39
17	A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas. <i>Annals of Thoracic Surgery</i> , 2019, 107, 393-400.	1.3	33
18	Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas. <i>Anticancer Research</i> , 2019, 39, 2665-2670.	1.1	9

#	ARTICLE	IF	CITATIONS
19	First Case of a Primary Lung Granulosa Cell Tumor With a Mutation in the Forkhead Box L2 Gene. <i>Journal of Thoracic Oncology</i> , 2019, 14, e100-e102.	1.1	0
20	A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase. <i>Journal of Thoracic Disease</i> , 2019, 11, 927-935.	1.4	14
21	Clinical and Prognostic Significance of the Epithelialâ€“Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Scoreâ€“Matched Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, e504-e513.	2.6	12
22	The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelialâ€“mesenchymal transition in resected lung adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0215103.	2.5	11
23	Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 1916-1924.	1.5	25
24	The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation. <i>Annals of Surgical Oncology</i> , 2019, 26, 1544-1551.	1.5	3
25	Spread through air spaces in lung neuroendocrine tumor. <i>Translational Lung Cancer Research</i> , 2019, 8, S439-S442.	2.8	0
26	HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome. <i>Transplant Immunology</i> , 2019, 53, 13-20.	1.2	1
27	ALK testing methods: is there a winner or loser?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 237-244.	2.4	10
28	The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 28, 735-743.	1.1	5
29	Surgical Repair of Pleuroperitoneal Communication with Continuous Ambulatory Peritoneal Dialysis. <i>Thoracic and Cardiovascular Surgeon</i> , 2019, 67, 147-150.	1.0	7
30	The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 1555-1563.	1.5	19
31	Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung. <i>Annals of Surgical Oncology</i> , 2018, 25, 1564-1571.	1.5	23
32	Significance of Spread Through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1655-1663.	1.3	76
33	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. <i>Surgical Oncology</i> , 2018, 27, 88-94.	1.6	41
34	Significance of Spread Through Air Spaces in Resected Lung Adenocarcinomas With Lymph Node Metastasis. <i>Clinical Lung Cancer</i> , 2018, 19, 395-400.e1.	2.6	25
35	Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 448-454.	1.3	15
36	Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1229-1236.	1.5	39

#	ARTICLE	IF	CITATIONS
37	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 116, 1-6.	2.0	51
38	Mucinous adenocarcinoma of the thymus: report of a case. <i>General Thoracic and Cardiovascular Surgery</i> , 2018, 66, 111-115.	0.9	14
39	Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-Cell Lung Cancer: A Mini-review. <i>Clinical Lung Cancer</i> , 2018, 19, 12-16.	2.6	62
40	Prognostic significance of immune-nutritional parameters for surgically resected elderly lung cancer patients: a multicentre retrospective study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 26, 389-394.	1.1	45
41	Invasive features of small-sized lung adenocarcinoma adjoining emphysematous bullae. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 372-378.	1.4	7
42	The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. <i>Clinical Lung Cancer</i> , 2018, 19, 120-129.	2.6	61
43	Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph node-positive lung cancer patients. <i>Cancer Science</i> , 2018, 109, 154-165.	3.9	36
44	Atezolizumab in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S3155-S3159.	1.4	4
45	PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 5897-5901.	1.1	17
46	Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 5903-5907.	1.1	11
47	Sarcopenia After Resection of Early Non-small Cell Lung Cancer: Is Postoperative Skeletal Muscle Loss a Risk Factor for Poor Outcomes?. <i>Annals of Surgical Oncology</i> , 2018, 25, 946-947.	1.5	1
48	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. <i>In Vivo</i> , 2018, 32, 1541-1550.	1.3	4
49	Radiological Features of IDO1 ⁺ /PDL1 ⁺ Lung Adenocarcinoma: A Retrospective Single-institution Study. <i>Anticancer Research</i> , 2018, 38, 5295-5303.	1.1	6
50	Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5093-5101.	2.0	43
51	The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score-matched analysis. <i>Cancer Medicine</i> , 2018, 7, 2860-2867.	2.8	4
52	Significance of spread through air spaces in early-stage lung adenocarcinomas undergoing limited resection. <i>Thoracic Cancer</i> , 2018, 9, 1255-1261.	1.9	27
53	Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1798-1799.	1.1	27
54	Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 101, 20-29.	2.8	35

#	ARTICLE	IF	CITATIONS
55	Computed tomography features of resected lung adenocarcinomas with spread through air spaces. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 1670-1676.e4.	0.8	65
56	A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 255-259.	2.0	14
57	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. <i>Surgical Oncology</i> , 2018, 27, 637-641.	1.6	10
58	Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 3707-3711.	1.1	9
59	Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation. <i>Anticancer Research</i> , 2018, 38, 3731-3734.	1.1	14
60	Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 553-557.	1.1	19
61	High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 1821-1825.	1.1	17
62	Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?. <i>Anticancer Research</i> , 2018, 38, 1041-1045.	1.1	5
63	Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors. <i>Anticancer Research</i> , 2018, 38, 1715-1719.	1.1	5
64	Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review. <i>Anticancer Research</i> , 2018, 38, 3115-3118.	1.1	1
65	Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 2957-2960.	1.1	2
66	High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas. <i>Clinical Lung Cancer</i> , 2017, 18, 504-511.e1.	2.6	12
67	The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2017, 18, e303-e313.	2.6	30
68	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2017, 18, 572-582.e1.	2.6	46
69	Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1750-1757.	1.3	25
70	Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression. <i>Clinical Lung Cancer</i> , 2017, 18, e375-e383.	2.6	18
71	The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. <i>Lung Cancer</i> , 2017, 104, 7-15.	2.0	69
72	Metabolic characteristics of programmed cell death ligand 1-expressing lung cancer on ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography. <i>Cancer Medicine</i> , 2017, 6, 2552-2561.	2.8	80

#	ARTICLE	IF	CITATIONS
73	Preoperative Geriatric Nutritional Risk Index: A predictive and prognostic factor in patients with pathological stage I non-small cell lung cancer. <i>Surgical Oncology</i> , 2017, 26, 483-488.	1.6	55
74	Wâ€™ALKâ€™™ Into the Next Stage. <i>Clinical Lung Cancer</i> , 2017, 18, 122-126.	2.6	6
75	The Efficacy of Ceritinib for <i>ALK</i>-rearranged Non-small Cell Lung Cancer Previously Treated with Alectinib -an Analysis of Japanese and Global Phase I Studies-. <i>Japanese Journal of Lung Cancer</i> , 2017, 57, 175-183.	0.1	0
76	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. <i>PLoS ONE</i> , 2017, 12, e0181598.	2.5	31
77	Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 2942-2951.	1.4	53
78	Pulmonary vein stump thrombosis after left pneumonectomy, diagnosed based on a high plasma D-dimer level: a case report. <i>Journal of Thoracic Disease</i> , 2017, 9, E210-E214.	1.4	5
79	Highlighted version successful resection of a tracheal metastasis of rectal cancer: a case report. <i>Journal of Thoracic Disease</i> , 2017, 9, E797-E800.	1.4	1
80	The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 741-748.	1.1	59
81	Radiological Features of the Surgically Resected Small-sized Small-cell Lung Cancer on Computed Tomography. <i>Anticancer Research</i> , 2017, 37, 877-882.	1.1	7
82	Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 1393-1402.	1.1	8
83	Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma. <i>Anticancer Research</i> , 2017, 37, 1729-1735.	1.1	7
84	Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation. <i>Anticancer Research</i> , 2017, 37, 2619-2623.	1.1	6
85	Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease. <i>Anticancer Research</i> , 2017, 37, 2735-2742.	1.1	24
86	Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 4223-4228.	1.1	30
87	Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab. , 2017, 37, 5713-5717.		24
88	Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 6997-7003.	1.1	25
89	Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 7073-7082.	1.1	32
90	Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients. , 2017, 37, 5871-5876.		3

#	ARTICLE	IF	CITATIONS
91	A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis. <i>Anticancer Research</i> , 2017, 37, 6937-6941.	1.1	2
92	Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1879-1890.	1.1	156
93	The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma. <i>Anticancer Research</i> , 2016, 36, 4841-4846.	1.1	10
94	An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria. <i>Anticancer Research</i> , 2016, 36, 3409-12.	1.1	25
95	Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 4329-36.	1.1	24
96	Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, e55-e57.	1.1	60
97	How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experience. <i>Surgical Oncology</i> , 2015, 24, 258-263.	1.6	16
98	Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data. <i>Oncology Research and Treatment</i> , 2015, 38, 291-298.	1.2	82
99	Role of surgical resection for patients with limited disease-small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 52-56.	2.0	61
100	Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 797-805.	5.9	86
101	Concurrent Chemoradiotherapy for Patients With Postoperative Recurrence of Surgically Resected Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 51-56.	2.6	25
102	Multimodality Treatment With Surgery for Locally Advanced Non-small-Cell Lung Cancer With N2 Disease: A Review Article. <i>Clinical Lung Cancer</i> , 2015, 16, 6-14.	2.6	16
103	Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, e86-e87.	1.1	69
104	ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non-small-Cell Lung Cancer?. <i>Clinical Lung Cancer</i> , 2014, 15, 313-319.	2.6	26
105	Cystic brain metastasis of non-small-cell lung cancer successfully controlled with Ommaya reservoir placement. <i>International Cancer Conference Journal</i> , 2013, 2, 89-92.	0.5	2
106	Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2013, 96, 1783-1789.	1.3	19
107	Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. <i>Cancer Science</i> , 2011, 102, 1298-1305.	3.9	170